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ABSTRACT
Although it is well known that RET gene is strongly
activated by retinoic acid (RA) in neuroblastoma
cells, the mechanisms underlying such activation
are still poorly understood. Here we show that a
complex series of molecular events, that include
modifications of both chromatin and DNA methyla-
tion state, accompany RA-mediated RET activation.
Our results indicate that the primary epigenetic
determinants of RA-induced RET activation differ
between enhancer and promoter regions. At
promoter region, the main mark of RET activation
was the increase of H3K4me3 levels while no sig-
nificant changes of the methylation state of H3K27
and H3K9 were observed. At RET enhancer region
a bipartite chromatin domain was detected in
unstimulated cells and a prompt demethylation
of H3K27me3 marked RET gene activation upon
RA exposure. Moreover, ChIP experiments
demonstrated that EZH2 and MeCP2 repressor
complexes were associated to the heavily
methylated enhancer region in the absence of RA
while both complexes were displaced during RA
stimulation. Finally, our data show that a
demethylation of a specific CpG site at the
enhancer region could favor the displacement
of MeCP2 from the heavily methylated RET
enhancer region providing a novel potential
mechanism for transcriptional regulation of
methylated RA-regulated loci.
INTRODUCTION
Retinoids play a critical role in cell proliferation, differen-
tiation and apoptosis in normal tissues during embryonic
development (1–3). Retinoic acid (RA) induces differenti-
ation in many cell types and is the most widely used
differentiating therapeutic agent (4). RA effects are
mediated by two families of nuclear RA receptors,
RARs and RXRs, which function as homo/heterodimers
and directly modulate transcriptional activity by binding
to RA responsive elements (RAREs) (5). Different studies
indicate that epigenetic modiﬁcations play important roles
in RA transcriptional regulation (6–10). In the absence of
RA, corepressive elements (SMRT, NCoR and Sin3A)
inhibit transcription while the presence of RA releases
corepressors and histone deacetylases allowing chromatin
remodelling and access to speciﬁc RAREs (8,9). Recently,
it has been reported that topoisomerase II and poly
(ADP-ribose) polymerase 1 collaborate to create a
double-strand break at a RA target promoter (RARB)
necessary for RAR-mediated transcription (11). The epi-
genetic dynamics of RA-induced Hox genes, that contain
canonical RARE in the enhancer regions, has been also
studied (12,13). It has been demonstrated that polycomb
group repressive complexes (PRC1 and PRC2/3) partici-
pate to transcriptional regulation of Hox genes. In par-
ticular, it is thought that trimethylation of lysine 27 (K27)
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of histone H3 (H3K27me3), caused by EZH2, a compo-
nent of PRC2/3 complex, serves as a binding site for re-
cruitment of PRC1 complex leading to repression of Hox
genes. Recently, it has been demonstrated that RA treat-
ment of F9 embryonal carcinoma cells causes recruitment
of pCIP, p300 and RNA polymerase II at target RAREs
occurring together with the displacement of SUZ12,
a component of PRC2/3 repression complex (13).
However, to date a limited number of information are
available on the epigenetic dynamics of RA response
compared to the extensive studies addressing the
dynamics of transcriptional activation mediated by other
nuclear receptors (most notably estrogen receptor) in
response to ligand (14,15)
In this work, we have investigated the major epigenetic
modiﬁcations occurring at RET locus in a neuroblastoma
cell line upon RA stimulation. Neuroblastic tumors show
dramatic neural maturation in response to RA through
the transcriptonal regulation of genes involved in the dif-
ferentiation process (16–19). In particular, RET, a
tyrosine kinase receptor, is consistently up-regulated
upon RA treatment of different neuroblastoma cell lines
(19). Because interference with RET activation affects the
whole RA-induced transcriptional and differentiation
programs (19), RET is considered to play a key role in
this process. The general structure of human RET gene
and the main regulatory elements have been partially
investigated and it has been reported that a conserved
enhancer region, located about 3000-bp upstream from a
promoter region, contains binding sites for Sox10 and
Pax3 transcription factors (20–22). However, the mechan-
isms leading to RET activation by RA in neuroblastoma
cells are still poorly understood. Here we show that a
complex series of epigenetics events, that include both
chromatin and DNA methylation modiﬁcations, accom-
pany RA-mediated RET activation.
MATERIALS AND METHODS
Cell culture
SK-N-BE cells were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium supplemented with 10% foetal bovine
serum (Life Technologies), 2mM glutamine, penicillin
(25U/ml) and streptomycin (25mg/ml) in a 5% CO2 at-
mosphere at 37C. All the treatments with all-trans RA
(Sigma-Aldrich) were performed using a 10 mM ﬁnal con-
centration. 5-Aza-2-deoxyazacytidine (ICN Biomedical
Inc.) treatments were performed for 48 h at 10 mM or
50 mM ﬁnal concentration.
Construction of fusion genes
pEISP-RET construct was obtained by amplifying the
Enhancer-IS-Promoter sequence of RET (nt 3221 to
+167) by PCR and then subcloned in the KpnI restriction
site of pGL3-basic Luciferase Vector (Promega). Primers
used were: EISP-KpnI/Fw: 50-ATTGGTACCAACCATG
CTTCTCAGTGCAGGC-30; EISP-KpnI/Rv: 50-ATT
GGTACCACGGCTGGAGGGACTGCGGCTAG-30
(underlined the restriction sites for cloning). Plasmids
pRARE-wt and pRARE-Mut were obtained cloning the
potential binding region of RARa (RARE), found by bio-
informatic search, into pGL3-promoter Luciferase Vector.
Primers used for the ampliﬁcation of RARE region
(RARE-wt, from 3178 to 3046) containing each a
DR of the identiﬁed putative RARE (bold) and a tag
with restriction sites for cloning (underlined), were:
RARE-wt-MluI/FW: 50-TTTAGACGCGTCCCCCATG
TCACCTGGGTCAGAGGAC-3; RARE-wt-XhoI/RV:
50-AAATGGCTCGAGGGAGCACCTCAGGTCTGAC
CCCAAAGC-30. pGL3-RAREwt was then generated by
inserting the MluI/XhoI digested amplicon in the same
sites of pGL3-promoter Luciferase Vector.
To obtain a mutant version of RARE region we used
other two oligos, similar to those indicated above, but
both carrying a mutation by deletion of three nucleotides
belonging to the DR (residued DR’s nucleotides are
indicated in bold): RARE-MUT-MluI/FW: 50-TTTAGA
CGCGTCCCCCATGTCACCTGGGGAGGACACAGA
GCATC-30; RARE-MUT-XhoI/RV: 50-AAATGGCTCG
AGGGAGCACCTCAGGTCCCCCAAAGCACCAAA
ACG-30. pGL3-RARE-Mut was then constructed by in-
serting the MluI/XhoI digested amplicon in the same sites
of pGL3-promoter Luciferase Vector. All constructs were
veriﬁed by DNA sequencing.
Transient transfections and luciferase assays
SK-N-BE cells were transiently transfected using
LipofectamineTM 2000 CD Reagent (Invitrogen) in a
24-well plates. At 70% of conﬂuence, in 500 ml of growth
medium, the cells were transfected with the reporter con-
struct pGL3-promoter Luciferase Vector (Promega).
Co-transfections were carried out in the presence of
200 ng of reporter construct and 200 ng of Renilla con-
struct and with or without 200 ng of pRARE-wt,
pRARE-Mut or pEISP-RET. Luciferase and Renilla
activities were measured with the dual-luciferase reporter
assay kit (Promega, Madison, WI, USA), and expressed as
relative to untreated control cells as Relative Luciferase
Units.
Statistical analysis
Statistical signiﬁcance between groups was assessed by
Student’s test. Data are expressed as means±SD. All ex-
periments were repeated at least three times. A P-value
<0.05 or <0.01 was considered to be statistically
signiﬁcant.
Antibodies
Antibodies used for all ChIP assays were: anti-H3Ac
(#06-599), anti di-methyl-H3K9 were from Upstate
(Upstate Biotechnology, Dundee; UK). Anti-RARa
(N-20, sc-551), anti-HDAC1 (C-19, sc-6298) and
anti-mSin3A (AK-11, sc-767) antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Anti-di-methyl-H3K4 (ab7766), anti-tri-methyl-H3K4
(ab8580), anti-tri-methyl-H3K9 (ab8898), anti-MeCP2
(ab2828), MBD2 (ab3754), anti-Dnmt1 (ab16632) and
anti-Dnmt3b (ab2851) were from Abcam Inc.
(Cambridge, MA, USA). Anti-tri-methyl-H3K27
(AM-0174-200) antibody was from Lake Placid
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Biologicals (Lake Placid, NY, USA) and anti-EZH2
(3147) antibody was from Cell Signaling (Danvers, MA,
USA). The speciﬁcity of anti-HDAC1, MeCP2, EZH2,
Sin3a, DNMT1 and DNMT3b antibodies was assessed
by western-blot analysis of SK-N-BE cell lysates (data
not shown).
Real Time RT–PCR
Total RNA was isolated with RNeasy extraction kit
Qiagen (Qiagen, GmBh) according to the manufacturer
instructions. The integrity of the RNA was assessed by
denaturing agarose gel electrophoresis and spectropho-
tometry. To ensure that RNA samples were not
contaminated by DNA, negative controls were obtained
by performing the PCR on samples that were not
reversed-transcribed but otherwise identically processed.
One microgram of total RNA of each sample was
reverse-transcribed with QuantiTect Reverse
Transcription (Qiagen) using an optimized blend of
oligo-dT and random primers according to the manufac-
turer’s instructions. Quantitative PCR ampliﬁcations were
performed using QuantiTect SYBR Green (Qiagen) in a
Chromo4 Real Time thermocycler (BIORAD). Following
primers were used for RET ampliﬁcations: RET1f
(forward) 50-TGCATCCAGGAGGACACC-30 and
RET1r (reverse) 50-TTGAGGTAGACGGTGAGC
AG-30. MeCP2: Hs_MECP2_1_SG QuantiTec primer
assay QT00039361 (Qiagen). G6PD gene was used as
housekeeping gene; following primers were used for
PCR reaction: G6PDf (forward) 50-GCAAACAGAGTG
AGCCCTTC-30 and G6PDr (reverse) 50-ggccagc
cacataggagtt-30. The conditions used for PCR were 2min
at 95C, and then 45 cycles of 20 s at 95C and 1min at
60C. Each reaction was performed in triplicates.
Calculations of relative expression levels were performed
using the 2Ct method (23) taking into account the
values of at least three independent experiments.
Gene silencing by RNA interference
SK-N-BE cells were plated at a density of 6 105 per
60-mm culture dish 24 h before transfections. Cells were
transfected with MeCP2 siRNA (Qiagen, Hs_MeCP2_7,
SI02664893, target sequence: ACGGAGCGGATTGCAA
AGCAA) or AllStars negative Control siRNA (Qiagen,
1027281) at a ﬁnal concentration of 5 nM using
HiPerfect Transfection reagent (Qiagen) according to the
manufacturer’s instructions. Cells were harvested after
48 h. RNA isolation and real-time PCR analyses were per-
formed as described earlier.
Quantitative ChIP analyses
Cells were cross-linked by adding 1% formaldehyde for
15min at room temperature in shaking. Glycine was
added to a ﬁnal concentration of 125mM for 5min at
room temperature in shaking. Cells were rinsed twice
with cold PBS supplemented with 500 mM PMSF and har-
vested in ﬁve pellet volumes of Cell Lysis Buffer (5mM
PIPES pH 8.0, 85mM KCl, 0.5% NP40) supplemented
with 1mM PMSF and CompleteTM protease inhibitors
mix (Roche). For each time point, four dishes containing
3–5 106 cells each, were utilized. Lysates were
incubated for 30min at 4C and then passed through 10
dounce cycles. They were subsequently centrifuged and
nuclei were collected. Nuclei were then resuspended in
Sonication Buffer (0.3% SDS, 10mM EDTA and
50mM Tris–HCl pH 8.0) supplemented with 1mM
PMSF and CompleteTM protease inhibitors mix (Roche,
Indianapolis, IN, USA) and incubated for 60min at 4C.
Chromatin was sonicated to an average DNA length of
400–600 bp using a 3mm (small size) tip equipped
Bandelin Sonoplus UW-2070 sonicator with 7 15 s
cycles of pulses (speciﬁc cycle 0.3, Power 30%) alternated
by 60 sec of rest. Sonicated samples were centrifuged and
the supernatant was collected. Eighty micrograms of chro-
matin were diluted with Dilution Buffer (0.01% SDS,
1.2mM EDTA and 16.7mM Tris–HCl pH 8.0),
precleared (2 h) by incubation with 20 ml Salmon Sperm
DNA/Protein A Agarose-50% Slurry (#16-157, Upstate)
and subjected to immunoprecipitation with speciﬁc
antibodies with rotation overnight at 4C.
Immunocomplexes were collected by adsorption onto
30 ml Salmon Sperm DNA/Protein A Agarose-50%
Slurry (#16-157, Upstate) and the beads were washed se-
quentially with Low Salt Washing Buffer (0.1% SDS,
2mM EDTA, 20mM Tris–HCl pH 8.0, 1% Triton
X-100 and 150mM NaCl) (4 times), High Salt Washing
Buffer (0.1% SDS, 2mM EDTA, 20mM Tris–HCl pH
8.0, 1% Triton X-100 and 500mM NaCl) (4 times) and
LiCl Washing Buffer (#20-156, Upstate). Precipitates were
washed with TE Buffer (10mM Tris–HCl pH 8.0 and
1mM EDTA), and antibody-chromatin fragments were
eluted from the beads with 1% sodium dodecyl sulphate
in 0.1M NaCO3. Cross-links were reverted by adding
200mM NaCl and heating at 65C overnight. 40mg/ml
RNase A and 20mg/ml proteinase K, 10mM EDTA
and 40mM Tris–HCl pH 6.5 were added and samples
were then incubated for 2 h at 45C. Samples were then
extracted in phenol-chloroform-isoamylic alcohol
(25:24:1), ethanol-precipitated and ﬁnally centrifuged at
13 000 rpm for 45min at 4C. Pellets were washed with
70% ethanol, centrifuged at 8000 rpm for 5min at 4C
and ﬁnally resuspended in 60 ml of H2O. For subsequent
PCR analysis, 2 ml of each sample were used as template.
Following primers were used for ampliﬁcation: EQuF 50-C
ACCGACCACTTTGCTAACAG-30 (position from nts
3475 to 3454) and EQuR 50-GGTGGTTGGAAGCA
CAGACT-30(position from 3435 to 3416) for the
analysis of enhancer region; IQuF 50-AGGAGCACAGC
CCCAGAT-30 (position from nts 1691 to 1674) and
IQuR 50-GCCCTTGGCTGACATTGA-30 (position from
nts 1636 to 1619) for IS; PQuF 50-ATTCGTGCGGA
GAGTTCTGTT-30 (position from nts+652 to+667) and
PQuR 50-CTGAGCGGGAAAAGGAAAC-30 (position
from nts+697 to+715) for promoter region; immunopre-
cipitations with IgG were used as negative controls. The
signals obtained by precipitation with the control IgG was
subtracted from the signals obtained with the speciﬁc
antibodies. Results are expressed as percentage of the
input, and calculations take into account the values of at
least three independent experiments.
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DNA methylation analysis
Genomic DNA was isolated with DNeasy extraction kit
(Qiagen) according to the manufacturer instructions.
Sodium bisulﬁte conversion was performed by using EZ
DNA Methylation Kit (Zymo Research). The manufac-
ture’s protocol was followed by using 2 mg of genomic
DNA and eluted in 30 ml of H2O.
Bisulphite genomic sequencing. Two microliters of each
sample was used as template in PCR reactions using the
following primers: EbiF 50-tagtggtagatagatgggaaattgag
g-30 (position from nts 3502 to 3476) and EbiR 50-cct
aaaacacctcaaatctaaccccaaaacac-30(from nts 3054 to
3023) for the analysis of RET enhancer region. PbiF
50-gagagtttttttgtgtaagggatgtaaggg-30 (position from nts
779 to 750) and PbiR 50-cccrcttacaatccctaccttttac
cctttcc-30 (from nts 389 to 358) were used for the
analysis of RET promoter region. Ampliﬁcations were
carried out on 10 ng of bisulphite treated DNA using
HotStarTaq DNA polymerase (Qiagen) under the follow-
ing conditions: 15min at 95C, followed by 50 cycles of
30 s at 95C, 52 s at 59C and 1min at 72C, then a ﬁnal
elongation of 10min at 72C before holding at 4C, in a
ﬁnal reaction volume of 30 ml. Conﬁrmation of PCR
product quality and freedom from contamination was es-
tablished on 2% agarose gels with ethidium bromide
staining. PCR ﬁnal products were then cloned into the
pGEM-T-easy vector provided by Promega pGEM-
T-Easy Vector System II (Promega Italia, Milan, Italy)
following the supplier’s procedures. Plasmid DNA was
puriﬁed using the Qiagen plasmid Mini Kit. The puriﬁed
plasmids were sequenced in both directions using T7 and
Sp6 primers. At least 20 independent clones were
sequenced to determine the methylation pattern of indi-
vidual molecules. Sequencing was performed at the
CEINGE Sequencing Core Facility.
Bisulﬁte analyses of MeCP2 immunoprecipitated DNA
(ChIP-BA) were performed as previously described (24)
using anti MeCP2 antibodies (ab2828-100, Abcam
Inc, Cambridge MA, USA). In this case primers EbiF
and EbiR2 (50-cacattcaaaaacrcaactcratcctaataatac-30)
(position from 3320 to 3287) were used for ampliﬁca-
tion of bisulﬁte treated coimmunoprecipitated DNA.
PyrosequencingTM analysis. Quantitative DNA methyla-
tion analysis was performed using the PSQ 96MA instru-
ment from Pyrosequencing (Biotage AB, Uppsala,
Sweden) following the protocol suggested by the manufac-
turer. The reactions were assayed on the PSQ
TM
96MA
using the SNP analysis software provided by the manu-
facturer. Primers used for PCR reactions were: EPyF
50-agggtagtggtagata-30 (position from nts 3506 to
3487) (50-Biotinylated) and EPyR 50- acycaactcyatccta
ataatac-30 (from nts 3298 to 3321). Ampliﬁcations
were carried out on 10 ng of bisulphite treated DNA
using HotStarTaq DNA polymerase (Qiagen) under the
following conditions: 15min at 95C, followed by
50 cycles of 30 sec at 95C, 52 sec at 59C and 1min at
72C, then a ﬁnal elongation of 10min at 72C before
holding at 4C, in a ﬁnal reaction volume of 30 ml.
Conﬁrmation of PCR product quality and freedom from
contamination was established on 2% agarose gels with
ethidium bromide staining. PCR ﬁnal products (208 bp)
were then used for Pyrosequencing reactions; sequencing
primers were: EPySeq1 50-cattcctaaaactactaac -30 (pos-
ition from nts 3354 to 3336) and EPySeq2
50-aactaactatatacactatt-30 (position from 3459 to
3440). Target CpGs were evaluated by analysis of the
resulting pyrograms. The analysis of a non-CpG cytosine
provided an internal control of the completeness of
bisulﬁte treatment.
SEQUENOM MassARRAY platform. This system
utilizes MALDI-TOF mass spectrometry in combination
with RNA base speciﬁc cleavage (MassCLEAVE). A de-
tectable pattern is then analyzed for methylation status.
PCR primers to analyze RET enhancer region (lower
strand), designed by using Methprimer (http://www.
urogene.org/methprimer) were: EmaF 50-aggaagagagTG
TTTTTTGATTTAGGTGATATGGG-30 and EmaR
50-cagtaatacgactcactatagggagaaggctAACCCCTCTAAAT
ACCCTAAAAACC-30. For reverse primer, an additional
T7 promoter tag for in vivo transcription was added, as
well as a 10-mer tag on the forward primer to adjust for
melting-temperature differences. The MassCLEAVE bio-
chemistry was performed as previously described (25).
Mass spectra were acquired by using a MassARRAY
Compact MALDI-TOF (Sequenom) and spectra’s methy-
lation ratios were generated by the Epityper software v1.0
(Sequenom). The whole procedure was performed at
Sequenom GmbH Laboratories (Hamburg, Germany).
Databases
RET gene sequences were retrieved by the Ensembl
database (accession number: ENSG00000165731).
RESULTS
RARa associates with the RET gene upstream regulatory
regions
It is known that RET gene is strongly activated by RA in
neuroblastoma cells (19). In order to investigate whether
RA receptors (RARs) can directly bind to RET regulatory
regions, we ﬁrst performed a bioinformatic analysis to
identify potential RA responsive elements (RAREs)
within the RET gene sequences (Figure 1A). Such
analysis showed that a potential RARE is located, on
the forward strand, at position 3178 to 3046 with the
respect of transcriptional start site (TSS). This RARE is
composed by two canonical hemi-sites but the distance
between the two half-sites was 121 nt and not 5 nt as
more frequently found in functionally characterized
RAREs (26). Consensus sequences represented by two
half-sites separated by up to 150 nt (DR150) have been
identiﬁed as functional RAREs (27). We then performed
chromatin immunoprecipitation (ChIP) experiments to
verify the presence of RARa, in RA-stimulated and un-
stimulated cells, at three different regions of RET locus
(Figure 1A): (i) the enhancer region located about 3.4-kb
upstream from the TSS, containing functional SOX10 and
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Pax3 binding sites (22) and displaying a putative complete
site for RARa binding; (ii) the promoter region, located
just upstream from the TSS and (iii) the genomic region
located between RET enhancer and promoter (intervening
sequences, IS). Activation of RET gene upon RA treat-
ment was veriﬁed by quantitative reverse transcriptase
PCR (qRT–PCR) in SK-N-BE cells (Supplementary
Figure S1). Results of ChIP experiments showed that
RARa was present, either in treated and untreated cells,
on both promoter and enhancer regions and not on IS
(Figure 1B). The amount of RARa protein bound to the
enhancer region slightly increased after 12 h of RA
treatment. These data suggest that RARa, although
stably associated to RET regulatory regions, may
promote transcription only in the presence of RA
possibly by inducing changes of chromatin conﬁguration.
Then we performed luciferase transcriptional assays in
order to investigate whether a 3.4-kb RET gene regulatory
region, located upstream from TSS and including both
promoter and enhancer, was sufﬁcient for RA responsive-
ness. The results, shown in Figure 2A, demonstrated that
plasmid constructs containing the 3.4-kb RET region
upstream the luciferase gene were more active than
empty plasmids (pGL3-basic); however, no signiﬁcant
increase of luciferase activity was observed when trans-
fected cells were treated with RA. Then, DNA fragments
of the RET enhancer region, containing either wild-type
or mutated putative RARE, were cloned into the
PGL3-promoter reporter plasmid that contains a SV40
promoter upstream from luciferase reporter gene. The
transcriptional assays showed that the fragments contain-
ing the wild-type putative RARE behaved as an enhancer
and promoted higher basal transcriptional activity, while
this ability was lost when the RARE was disrupted
(Figure 2B). However, neither the wild-type nor the
mutated fragments were able to confer RA responsiveness
to the reporter plasmids. Taken together, these results sug-
gested that the presence of other genomic regions, not
included in our constructs, were likely necessary for RA
responsiveness possibly through the formation of chroma-
tin loops that may bring together distant genomic regions
and may account for the presence of RARa protein
detected by our ChIP experiments at RET enhancer. In
addition, possible epigenetic modiﬁcation occurring at the
endogenous gene, and not on transiently transfected con-
structs, may play a critical role in RA responsiveness.
Thus, in order to investigate the relative contribution of
RET 3.4-kb upstream region to RA responsiveness, we
decided to investigate chromatin and DNA methylation
changes that may occur at 3.4-kb RET regulatory region
during RA-mediated activation.
RA induces multiple epigenetic modiﬁcations restricted
to RET promoter and enhancer
In order to study possible chromatin changes occurring
during RET gene activation, we determined by a series
of ChIP assays coupled with qRT–PCR, the histone modi-
ﬁcation state at the RET regulatory regions after different
times of RA treatment. The major histone modiﬁcations
were analyzed. First, we analyzed di- and trimethylated
lysine 4 on histone H3 (H3K4me2, H3K4me3) whose
increase is commonly associated with gene activation.
Surprisingly, H3K4me2 levels were high prior to RA treat-
ment and sharply decreased in concomitance with RET
activation on both enhancer and promoter regions
(Figure 3). However, at promoter region, such decrease
was balanced by an increase of the trimethylated form
(H3K4me3) while, at enhancer, no signiﬁcant changes of
H3K4me3 was observed. The speciﬁcity of these events for
the regulatory regions was conﬁrmed by the analysis of the
same histone modiﬁcations at the IS, where no changes
were observed (Figure 3). These results suggest that
Figure 1. RARa association to RET gene regulatory regions.
(A) Bioinformatical analysis. In the aim to ﬁnd putative RARE we
performed the analysis on both forward and reverse strand of the
genomic region located between 5000 to +5000 nt positions with
respect of RET trascriptional start site. We searched for all
50-PuG[G/T]TCA-30 motifs (half-sites) and considered only exact
directly repeated half-sites separated by up to 150 nt as potential
RARE sites. With these criteria only one putative RARE was identiﬁed
on the forward strand, at position from 3178 to 3046, as indicated
in the ﬁgure. E, Enhancer region; I, intervening sequences; P, Promoter
region. (B) SK-N-BE cells were treated for 1 or 12 h with 10 mM RA or
were left untreated (Time 0). ChIP experiments were performed with
anti-RARa antibodies or with IgG (as negative control) and with
region-speciﬁc primers (EQF and EQR for enhancer; IQF and IQR
for IS; PQF and PQR for promoter). Primers to RAREs of human
RARB and primers to exon 2 of the same gene were used as positive
and negative controls, respectively. RARa levels at RARB RARE was
about 30 times the level of association detected at RARB exon 2 (data
not shown). Each experiment was repeated at least three times, and the
quantitative PCR analyses were performed in triplicate. The data are
presented as percentages of input DNA (mean±SE).
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consistent changes of methylation state of H3K4, that are
speciﬁc for regulatory regions but differ between promoter
and enhancer, accompany RET activation. In light of
recent observations of cyclic histone modiﬁcations at
estrogen- and androgen-regulated genes regulatory
regions (28), it is interesting to note that the levels of
H3K4me3 clearly cycled at RET promoter region during
RA-mediated gene activation (Figure 3). Then, we
analyzed the methylation state of H3K9 which is
commonly considered a transcription repression marker
(29). Results showed that the levels of both H3K9me2
and H3K9me3 strongly increased at the enhancer region
during RA stimulation while no signiﬁcant changes were
observed at promoter region (Figure 3). Remarkably, the
observed dynamics of H3K9 methylation at enhancer
region, during the ﬁrst 3 h of RA treatment, were in
conﬂict with the widely reported role of these histone
modiﬁcations as repressive markers. However, it is to be
noted that after 6 h of RA treatment, H3K9me3 levels
sharply decreased suggesting that the simultaneous
increase of H3K9me2 levels was a consequence of
H3K9me3 demethylation. Unlike H3K4me3, the changes
in H3K9me2 and H3K9me3 levels did not appear to cycle
during RA-mediated gene activation in the analyzed RET
gene regions. The analysis of the IS region showed that no
changes of H3K9me2 or H3K9me3 levels occurred upon
RA treatment, thus conﬁrming that the observed events
were speciﬁc for the regulatory regions. Furthermore, we
analyzed the levels of trimethylated H3K27 (H3K27me3)
that are commonly associated with gene repression (30,31)
and have been recently shown to play a role in RA
response (32,33). Results of ChIP experiments showed
that H3K27me3 was present at high levels only at the
RET enhancer region in the absence of RA stimulation
and a strong decrease of H3K27me3 accompanied RET
gene activation. No signiﬁcant changes of H3K27me3
were detected at IS nor at promoter regions. Finally, we
analyzed the acetylation state of histone H3. As expected,
although with a different dynamics, a cyclic increase of
acetylation at both promoter and enhancer regions was
observed during RA stimulation (Figure 3). Again, no
changes of acetyl-H3 levels were detected at the IS con-
ﬁrming the speciﬁcity of the events observed at the
enhancer and promoter regions. Interestingly, the levels
of H3K27me3 and of acetyl-H3 clearly cycled at
enhancer and promoter regions, respectively (Figure 3).
Figure 2. Transcriptional assays for RA responsiveness. (A) The region containing RET enhancer, intervening sequence and promoter (3.4 Kb) was
ampliﬁed and cloned into pGL3-basic Luciferase Vector (pEISP-RET). Right panel: Relative Luciferase Assay results on SK-N-BE cells transfected
with 200 mg of corresponding construct represented in the left panel. Plasmid constructs are described in ‘Materials and Methods’ section.
(B) A 150-bp fragment including the putative RARE sequence identiﬁed on the basis of bioinformatic analysis was cloned both as wild-type
(pRARE-wt) and in a mutated form (pRARE-Mut) in a pGL3-promoter Luciferase Vector. Two hundred micrograms of three different constructs
were transfected into SK-N-BE cells (left panel): pGL3-promoter Luciferase Vector (empty); pGL3-promoter Luciferase Vector containing the
putative RARE and pGL3-promoter Luciferase Vector containing the putative RARE lacking the triplette TCA in both DRs. Plasmid constructs
are described in details in ‘Materials and Methods’ section. After transfection, cells were treated with RA (10 mM) for different times followed by
luciferase activity determination. All tranfections were performed in triplicate; luciferase activity was detected 0, 6 and 12 h after RA exposure.
Data are means±SD of three independent experiments. E, Enhancer; IS, Intervening Sequences; P, Promoter; *P< 0.01; **P< 0.05.
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RA induces the displacement of EZH2 and DNMTs from
heavily methylated RET enhancer
The ﬁnding that the H3K27me3 levels play a key role in
driving chromatin changes at enhancer region during RET
gene activation prompted us to investigate whether EZH2,
a H3K27 histone methyltransferase, was involved in RET
transcriptional control. ChIP experiments using
anti-EZH2 speciﬁc antibodies showed that, in untreated
cells, EZH2 was present at high level on the enhancer
region. These ﬁndings were consistent with the observed
H3K27 methylation state at enhancer region. Upon RA
treatment, the levels of EZH2 at enhancer region
decreased together with the observed H3K27me3
demethylation (Figure 3). Interestingly, cycling of both
H3K27me3 and EZH2 levels was observed after the
initial decrease at the enhancer region. At promoter
region, signiﬁcant EZH2 binding was also detected
(Figure 4).
Figure 3. Dynamics of RA-dependent chromatin modiﬁcations at RET gene regulatory regions. SK-N-BE cells were treated for the indicated times
with 10 mM RA and then cells were ﬁxed with formaldehyde and processed into soluble chromatin. Chromatin samples were immunoprecipitated
with the indicated antibodies and bound DNA was quantitated by real time PCR. Each experiment was repeated, starting with cell culture, at least
three times, and the quantitative PCR analyses were performed in triplicate. The data are presented as percentages of input DNA (mean±SE).
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Since EZH2 may act in concert with DNA
methyltransferase (DNMTs), we performed additional
ChIP analysis using DNMT1 and DNMT3b antibodies.
During the same time-course, a binding behavior similar
to that displayed by EZH2 was observed for DNMT1
(Figure 4) and DNMT3b (data not shown) at enhancer
sequences while no consistent binding of both DNMTs
was detected at both IS and promoter region upon RA
treatment.
Taken together these results suggest that at promoter
region EZH2 might be enzymatically inactive, possibly
because the proteins to which EZH2 associates at
promoter region differ from those associating at
enhancer region. This hypothesis is also corroborated by
the observation that DNMT1 and DNMT3b, that may be
part of the Polycomb Repressor Complex (PRC2) to
which EZH2 belongs (34), are recruited on the enhancer
while are absent at the promoter region.
DNA methylation state of RET gene
Next, because EZH2 association with DNMTs may have
a role in the control of DNA methylation (34), we
analyzed the DNA methylation state of RET regulatory
genomic regions in SK-N-BE cells. A schematic represen-
tation of RET regulatory regions including CpG distribu-
tion and indication of the analyzed regions is shown in
Figure 5A. Bisulﬁte genomic sequencing showed that
enhancer region was heavily methylated while promoter
region was almost unmethylated (Figure 5B) consistently
with the observed differential localization of EZH2.
In order to investigate whether the observed DNA methy-
lation proﬁles at the RET locus were a speciﬁc feature of
SK-N-BE cell line or resembled those present in human
tissues, we analyzed both non-expressing (normal thyroid)
and expressing (medullary thyroid carcinomas) human
tissues. Results showed that CpG methylation at RET
locus displayed a similar distribution among expressing,
non-expressing tissues and SK-N-BE cells (Figure 5C).
However, in medullary thyroid carcinomas the methyla-
tion degree at enhancer region was signiﬁcantly lower
compared to non-expressing thyroid tissue and
SK-N-BE cells. Finally, treatment of SK-N-BE cells
with a demethylating agent (5-aza-2-deoxyazacytidine),
led to an increase of RET expression even in the absence
of RA (Supplementary Figure S2). Overall, a possible in-
terpretation of these data was that DNA methylation state
of the RET enhancer region may contribute to gene re-
pression in unstimulated cells and that full activation of
RET gene may be achieved in RA-treated SK-N-BE cells
by inducing chromatin remodelling at the heavily
methylated enhancer region.
RA induces displacement of MeCP2/HDAC1/Sin3A
complex from RET enhancer facilitating transcription
We next investigated possible mechanisms allowing the
observed modulation of chromatin conﬁguration at
enhancer region despite its heavily DNA methylated
status. Since methyl-binding proteins are the major inter-
preters of DNA methylation exerting their role by binding
to methylated DNA and promoting closed chromatin con-
ﬁguration, we hypothesized that these proteins could be
involved in the regulation of RET gene. We performed
ChIP experiments at different times of RA treatment of
SK-N-BE cells using anti-MeCP2 and anti-MBD2
antibodies. While MBD2 was not present in the RET
regulatory regions (data not shown), MeCP2 was specif-
ically associated to the heavily methylated enhancer region
(Figure 6A). Remarkably, upon RA treatment a strong
decrease of MeCP2 binding to the enhancer region was
observed in concomitance with RET activation. Since
MeCP2 is frequently associated to a chromatin repressor
complex including HDAC1 and Sin3A, we investigated
the role of these proteins during RET activation by
ChIP assays. We found that both HDAC1 and Sin3A
were present on enhancer region before RA treatment
and both were displaced in concomitance with RET acti-
vation (Figure 6B and C). These data are consistent with
the hypothesis that RA may induce displacement of
MeCP2 and associated proteins from methylated DNA
favoring changes of chromatin conﬁguration from closed
to open state.
Site-speciﬁc DNA demethylation at RET enhancer region
follows RA treatment and interferes with MeCP2 binding
Next, we investigated whether the observed decrease of
MeCP2 from the heavily methylated enhancer region
upon RET activation could be associated to changes in
DNA methylation state. We performed genomic bisulﬁte
sequencing analysis to monitor the methylation degree of
Figure 4. EZH2 and DNMT1 binding to RET regulatory regions.
SK-N-BE cells were treated for the indicated times with 10 mM RA.
ChIP experiments were performed using anti-EZH2 and anti-DNMT1
antibodies and bound DNA was quantitated by real time PCR. Data,
presented as percentages of input DNA before immunoprecipitation,
represent the results of three independent experiments±SEMs.
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10 CpG sites within the enhancer region (from 3502 to
3023) at different times after RA treatment. Very inter-
estingly, we found that starting at 1 h, a speciﬁc CpG sites
(position 3375) underwent partial demethylation
(Figure 7 and data not shown). These data were conﬁrmed
by independent quantitative methylation analyses using
MassARRAY and pyrosequencing techniques (Figure 7
and data not shown). Next, in order to investigate
in vivo whether the methylation state of 3375 CpG site
had some inﬂuence on MeCP2 binding to the enhancer
region, we performed a ChIP using anti-MeCP2
antibody followed by bisulﬁte methylation analysis
(ChIP-BA) (24). Results shown in Figure 7C indicated
that, after 3 h of RA treatment of SK-N-BE cells, DNA
molecules immunoprecipitated with MeCP2 displayed
100% of methylation at 3375 CpG site while in the
input DNA the methylation degree at the same site
was 50%. Interestingly, the methylation state of the two
adjacent CpG sites remained almost constant. These
results suggest that the unmethylated state of 3375 site
in the RET enhancer region can interfere with MeCP2
binding.
Next, in order to conﬁrm an active role of MeCP2 in
RET gene silencing in cells not treated with RA, we per-
formed MeCP2 knock-down experiments. SK-N-BE cells
were transfected with MeCP2 speciﬁc siRNA and the
mRNA expression of RET and MeCP2 (as a control)
were measured by qRT-PCR (Figure 8A). We found
that MeCP2 mRNA levels were reduced to about 30%
of initial levels while RET expression showed a 3-fold
increase even in the absence of RA treatment
(Figure 8A). Finally, we evaluated by ChIP analysis, the
occupancy of MeCP2 at the enhancer region after the
SK-N-BE cells were treated with 5-Azacytidine, a DNA
demethylating agent. SK-N-BE cells were treated with
10 mM or 50 mM 5-aza-2-deoxyazacytidine for 48 h. As a
Figure 5. Methylation analysis of RET enhancer and promoter regions in SK-N-BE cells, human normal thyroid tissue and medullary carcinomas.
(A) Schematic representation of CpG distribution at RET regulatory regions. Each vertical bar indicates the relative position of a CpG site.
Transcription start site is indicated (+1). The speciﬁc regions analyzed for DNA methylation state are indicated by horizontal bars. Primers used
for enhancer (EbiF and EbiR) and promoter (PbiF and PbiR) methylation analysis are reported in ‘Materials and Methods’ section. (B) DNA
methylation patterns in individual PCR clones from the RET enhancer and promoter. All the sequenced molecules from SK-N-BE cells are shown.
Numbers on top show the location of CpG dinucleotides. Black circles indicate that the corresponding cytosines are methylated. (C) Percentage of
DNA methylation at individual CpG sites in the RET gene enhancer (left panel) and promoter (right panel) in SK-N-BE cells, human normal
thyroid tissue (thyroid) and medullary thyroid carcinoma (MTC). Data, from the sequence analysis of least 20 plasmid clones for each sample, were
compiled by individual CpG dinucleotides and expressed as the ratio of methyl-C to the number of clones. Positions of CpG sites relative to
transcription initiation site are given below the bars.
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control, we found by bisulphite analysis that the average
DNA methylation of 10 CpG sites located in the enhancer
region decreased from 93 to 25% and 16%, respectively.
In these conditions, as demonstrated by ChIP experiments
shown in Figure 8B, the levels of MeCP2 bound to the
enhancer region were found to be drastically reduced.
Overall, these data support the hypothesis that RA
induces changes in DNA methylation state of speciﬁc
CpG sites at RA responsive genes which, in turn, favor
the release of MeCP2 and, consequently of the chromatin
repressor complex.
DISCUSSION
In this work we have performed for the ﬁrst time a sys-
tematic analysis of the main epigenetic modiﬁcations ac-
companying RET gene activation in a neuroblastoma cell
line upon RA stimulation. First, we found that a 3.4-kb
region upstream from TSS and containing a putative
RARE, although not sufﬁcient to provide RA responsive-
ness in luciferase reporter assays, instead, in the genomic
context could bind RARa and was subject to several chro-
matin and DNA methylation changes upon RA-mediated
RET activation. We found that, for some aspects, the
chromatin dynamics did not follow the general rules
described for genes activated by different nuclear recep-
tors, such as estrogen or androgen receptors which, in
contrast to RA responsive genes, have been thoroughly
investigated (14,15). Most of reports indicate that
increase in H3K4me2 and acetyl-H3 as well as decrease
in H3K9me3 and H3K27me3 levels mark transcriptionally
active chromatin structure. Our results indicate that the
primary epigenetic determinants of RA-induced RET ac-
tivation differ between enhancer and promoter regions. At
promoter region, the main driver of RET activation
appears to be the increase of H3K4me3 levels while no
signiﬁcant changes of the methylation state of H3K27
and H3K9 were observed. Acetylation of histone H3
increased at both enhancer and promoter regions in con-
comitance with RET activation, which is in agreement
with previous reports (20). At RET enhancer region we
observed a simultaneous presence of histone modiﬁcations
associated with transcriptional repression (H3K27me3)
and activation (H3K4me2) (Figure 3). Interestingly,
genomic regions containing this so called ‘bivalent chro-
matin domain’ have been recently mapped and shown to
be associated in particular with developmental genes and
with highly conserved noncoding elements (35). We show
that during RA treatment the prominent epigenetic modi-
ﬁcation at RET enhancer region was the demethylation of
H3K27me3, while H3K9me3 demethylation occurred at
later times (6 h of RA exposure) following an initial con-
sistent increase observed in the earlier phases (Figure 3). A
signiﬁcant demethylation of H3K4me2 was also observed
at the enhancer region. A similar chromatin dynamics,
including demethylation of H3K27me3, has been
recently described for other RA regulated loci (Hoxa1,
Cyp26A1 and RARb2) in F9 embryonal carcinoma cells
(13). However, in this study it was observed that
H3K4me2 levels remained constant during RA treatment
while the methylation state of H3K9 was not investigated.
A possible explanation of the non-conventional
Figure 6. Association of MeCP2 repression complex with RET gene regulatory regions. SK-N-BE cells were treated for the indicated times with
10 mM RA. ChIP experiments were performed using anti-MeCP2 (A), anti HDAC1 (B) and anti mSin3A (C) antibodies. Bound DNAs were
quantitated by real time PCR. Data, presented as percentages of input DNA before immunoprecipitation, represent the results of three independent
experiments± standard error of the means.
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modiﬁcations observed at RET gene enhancer is that the
DNA methylation state of this region might inﬂuence the
chromatin dynamics during the transition from a repres-
sive to an active state. In fact, our data show that RET
enhancer region is heavily methylated in SK-N-BE cells
and it is well established that dense CpG methylation has
a direct impact on local chromatin state, a connection
which is mediated by methyl-binding proteins that retain
the ability to recruit chromatin repressor complexes on
methylated DNA. Thus, it is likely that chromatin
changes occurring at highly methylated genomic regula-
tory regions in the course of gene activation may follow
different rules from those occurring at low methylated or
unmethylated regions. In this work we have then ad-
dressed different questions regarding the role of DNA
methylation in the control of RET gene expression. First
we found that heavily methylated state of RET enhancer
was not a speciﬁc feature of the cell line used in this study
since a similar distribution of CpG methylation status it
was observed in human tissues. However, we observed
that medullary carcinomas, which constitutively express
RET gene, showed an average methylation degree at 12
CpG sites in the enhancer region of 60% versus an average
of 90% observed in non-expressing thyroid tissues and in
SK-N-BE cells in which RET expression is inducible by
RA (Figure 5). All these data together with the observed
ability of demethylating drugs to partially reactivate RET
gene in SK-N-BE even in the absence of RA stimulation,
led us to conclude that DNA methylation at enhancer
region may contribute to RET gene repression even
though this repressive state may be overcome by
RA-induced epigenetic modiﬁcations. Secondly, the sim-
ultaneous presence at RET enhancer of H3K27me3 modi-
ﬁcation and highly methylated CpGs status prompted us
to investigate a possible role of EZH2, a component of
PRC2/3 complex, in the determination of such epigenetic
features at RET locus. In fact, EZH2 is a H3K27
methyltransferase that has been shown to drive DNMTs
at its target loci (34). Moreover, we observed that the
levels of EZH2 bound to enhancer region signiﬁcantly
decreased upon RA treatment of SK-N-BE cells in con-
comitance with decreased H3K27me3 levels and gene ac-
tivation. These data strongly suggest that alleviation of
PcG repression may play a critical role in RA-mediated
Figure 7. Demethylation of a speciﬁc CpG site at RET gene enhancer region upon RA treatment. (A) Schematic representation of CpG distribution
at RET enhancer. Each vertical bar indicates the relative position of a CpG site. The approximate position of the primers utilized for bisuﬁte,
MassARRAY and pyrosequencing quantitative methylation analyses are indicated (see ‘Materials and Methods’ section for primer speciﬁcations).
Numbering is referred to TSS. (B) SK-N-BE cells were left untreated (UN) or treated with RA for the indicated times and then methylation analyses
were performed on bisulﬁte treated genomic DNA. Data shown represent the results of three independent methods for quantitative methylation
analyses (bisulﬁte, manual genomic sequencing; Sequenom MassARRAY quantitative methylation analysis; Pyrosequencing quantitative methylation
analysis). For manual genomic sequencing, data, from the sequence analysis of at least 20 plasmid clones for each sample, were compiled by
individual CpG dinucleotides and expressed as the ratio of methyl-C to the number of clones. Further details for Sequenom MassARRAY and
pyrosequencing are reported in ‘Materials and Methods’ section. The results for three CpG sites including the 3375 and adjacent CpG sites,
according the three different procedures, are shown as percentage of DNA methylation at individual CpG sites in the RET gene enhancer. (C) ChIP
followed by bisulﬁte analysis (ChIP-BA). SK-N-BE cells were treated with RA for 3 h (3 h) or left untreated (UN) and then ChIPs were performed
using anti-MeCP2 antibodies. Input and immunoprecipitated DNAs were subjected to genomic sequencing bisulﬁte methylation analysis using EBiF
and EbiR2 primers (see ‘Materials and Methods’ section). Data were from the sequence analysis of at least 20 plasmid clones for each sample and
expressed as the ratio of methyl-C to the number of clones. Shown are the percentages of methylation of three CpG sites.
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RET activation. Another interesting aspect emerging from
our data is that the levels of some histone modiﬁcations
cycled at RET gene during RA-mediated activation. The
levels of the main active marks, H3K4me3 and H3ac,
clearly cycle at promoter region. Interestingly, these two
active marks behave anti-correlated at early time-points
(30–60min) while they correlate at later time points. In
addition, the levels of EZH2 were shown to cycle at
enhancer region and correlate with the H3K27me3 levels.
Finally, because it is largely believed that densely
methylated DNA region correspond to highly compacted
chromatin conﬁguration, we worked on the hypothesis
that changes of DNA methylation state or modulation
of the association of methyl-binding proteins to
methylated DNA were necessary for chromatin transition
from a closed to an open state. In previous works, we
found that MBD2 binding to methylated DNA, and not
DNA methylation state, may be affected by the presence
of other proteins leading to reactivation of methylated
genes (36,37). In this work we found that MBD2 is not
involved in RET gene regulation but we demonstrate that
both a site-speciﬁc CpG demethylation and the release of
MeCP2 from methylated RET enhancer accompanied
changes of histone modiﬁcations and RET gene activa-
tion. An active role of 3375 CpG site demethylation in
favoring MeCP2 release is supported by the analysis of
methylation state of this CpG site in MeCP2 immunopre-
cipitated DNA showing an enrichment in DNA bearing
methylated 3375 CpG site compared to input DNA
(Figure 7) and by the observation that this CpG site
showed a low methylation degree in the RET expressing
tissues (Figure 5). Very interestingly, a similar mechanism
has been well established for the activation of brain
derived nerve-growth factor (BDNF) gene in rat neurons
following calcium inﬂux (38–40). In this case, the release
of MeCP2 from BDNF promoter (promoter IV) is neces-
sary for transcriptional activation and appears to be
mediated by both a site-speciﬁc CpG demethylation
(38,40) and by phosphorylation, by a CaMKII-dependent
mechanism, of a speciﬁc residue (S421) of MeCP2 protein
(39). The possibility that post-translational modiﬁcation
of MeCP2 could be involved also in the RA-induced
release of MeCP2 from methylated RET enhancer and,
possibly, other RA target loci, deserves to be explored.
In any case, the observed displacement of MeCP2 from
RET enhancer may not only facilitate the transcriptional
activation but also help to establish and stabilize a
reprogramming of gene expression following RA
exposure. At this stage, our data support a novel
intriguing mechanisms in which RA induces changes in
DNA methylation state of speciﬁc CpG sites at RA re-
sponsive genes that, in turn, favor the release of MeCP2
and, consequently of the chromatin repressor complex. In
this scenario, the heavily methylated state of RET
enhancer region, found in both expressing and
non-expressing tissues, would represent an epigenetic
regulatory feature of RET enhancer rather than a simple
repressive signal. The possible active involvement of
MeCP2 binding in the regulation of methylated RA
target genes, as suggested by our data, could have import-
ant implications both in normal development and in
neurodevelopmental disorders and deserves further
investigations.
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Figure 8. MeCP2 contribution to RET gene silencing. (A) MeCP2
knock-down. SK-N-BE cells were transfected with MeCP2 or a
negative control siRNA and after 48 h the RET and MeCP2 mRNA
levels were analyzed by RT–PCR. Results are expressed as fold induc-
tion compared with control untransfected cells (Control). The experi-
ments were repeated three times and quantitative PCR analyses were
performed in triplicates. Error bars represent standard deviation.
(B) Effects of 5-aza-2-deoxyazacytidine on MeCP2 binding to RET
enhancer. SK-N-BE cells were treated with 5-aza-2-deoxyazacytidine
(dAZA) for 48 h at the indicated concentrations and were immunopre-
cipitated with anti-MeCP2 antibodies (black bar). Anti-IgG were used
as a negative control (gray bar). The MeCP2 binding to RET enhancer
was quantitated by real-time PCR. Data, presented as percentages of
input DNA, represent the results of three independent experi-
ments± standard error of the means.
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